Abstract: A method for ablating cancerous tissue in a subject, the method comprising incorporating a sound excitable compound into said cancerous tissue followed by exposure of said cancerous tissue to low-intensity ultrasound having an intensity of no more than 5 W/cm2, said sound excitable compound having the structure Formula (1) wherein: X1, X2, X3, and X4 are each independently selected from iodine and bromine atoms; X5, X6, X7, and X8 are each independently selected from hydrogen atom, chlorine, bromine, and iodine atoms; Y1 is an —O—, —NR?—, or —CR?2— linker, wherein R? is independently selected from hydrogen atom and methyl; Z is a hydrocarbon linking group containing 1-12 carbon atoms; R1 is selected from hydrogen atom, methyl, —OH, and —OR groups, wherein R is an alkyl group containing one to three carbon atoms; and wherein said Formula (1) includes pharmaceutically acceptable salts and solvates of the compounds embraced by Formula (1).

Abstract: Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3? or C4? modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

Abstract: The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed include crystalline (S)-2-amino-N-((3R,5R)-8-hydroxy-6-oxo-7-oxa-1-aza-8-boraspiro[4.7]dodecan-3-yl)-3-methylbutanamide in Form D and in Form E: (3R,5R)-8-hydroxy-3-((S)-4-isopropyl-2,2-dimethyl-5-oxoimidazolidin-1-yl)-7-oxa-1-aza-8-boraspiro[4.7]dodecan-6-one or a pharmaceutically acceptable salt thereof or the crystalline Form 1 thereof: and pharmaceutical compositions and methods of using the same.

Abstract: The present invention is directed to a polymer comprising a first hyaluronic acid (HA) chain and a second HA chain crosslinked via a linker comprising an unsaturated moiety or a derivative thereof coupled to a tetrazine moiety or a derivative thereof. In some embodiments, the polymer of the invention is characterized by having a crosslinking degree of 0.2 to 4%.

Abstract: The present invention relates to the use of adenosine receptor modulators to affect the circadian rhythm, in particular, to the use of such modulators for the treatment of circadian rhythm disorders. In particular, the invention relates to a composition comprising at least one selective adenosine receptor modulator, wherein said composition modulates two or three, but not all of adenosine receptor subtypes A1, A2A, A2B and/or A3 for use in the treatment of circadian rhythm disorders or for modulating a biological clock.

Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.

Abstract: The disclosure provides for means for a method to facilitate food intake and food retention in a mammal by applying a sufficient dose of a local anesthetic drug in the lumen of the pharyngeal-esophageal-gastric-duodenal tract before or during or after eating. The local anesthetic can be amethocaine, articaine, benzocaine, bupivacaine, chloroprocaine, cinchocaine, cyclomethycaine, dibucaine, diethocaine, etidocaine, larocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, novocaine, piperocaine, prilocaine, procaine, proparacaine, propoxycaine, QX-222, QX-314, ropivacaine, tetracaine, trimecaine, menthol, eugenol or a safe pharmaceutical formulations of tetrodotoxin, saxitoxin, or neosaxitoxin. The disclosure is useful for patients having problems with food intake or food retention.

Abstract: Described herein is an isolated biological polysaccharide compound. The biological polysaccharide compound may be characterised by being isolated and having: glycosyl linkages comprising 1:3 linked glucopyranosyl residue of 65-95% wt and 1:6 linked glucopyranosyl residue of 5-25% wt; and a purity of 85-100% ?-glucan; and a molecular weight of 0.5 to 2.2 MDa; and a TNF-alpha cytokine response in a human bioassay that is at least 1.5 times greater than a negative control TNF-alpha cytokine response in a human bioassay; and being essentially insoluble in aqueous solutions. In at least one embodiment, methods are described of treating skin by topical application of a vehicle containing the isolated biological polysaccharide to a skin site such as a wound or burn. A method of manufacture is also described.

Abstract: Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.

Abstract: An industrialization method for comprehensive utilization of Stevia rebaudiana. The major improvement is in that the Stevia rebaudiana is extracted by using a high-concentration alcohol solution, then the extracted solution is purified by using an organic solvent, and the pH of the extracted solution is adjusted to be alkaline according to the acidic characteristic of chlorogenic acid to enable the chlorogenic acid to be formed into a salt and have an increased polarity so as to achieve effective separation of the chlorogenic acid and a glucoside component in an adsorption process. The method allows the high-quality stevioside and chlorogenic acid to be obtained, significantly improves the comprehensive utilization rate of Stevia rebaudiana, reduces the waste of natural Stevia rebaudiana resources, reduces the resource consumption in a production process, reduces waste discharge, and is a high-benefit green production process.

Abstract: This invention claims ribonucleosides and their derivatives, including triphosphates, that have a 3?-ONH2 moiety instead of a 3?-OH moiety.

Abstract: The present invention describes an efficient way to isolate a sialic acid from a fermentation broth. The sialic acid contained in the fermentation broth is produced by bacterial fermentation. The inventive process comprises a step of removing biomass from the fermentation broth, a step of subjecting the resulting solution to at least one of a cationic ion exchanger treatment and an anionic ion exchanger treatment and a step of removing salts after the ion exchanger treatment. The process can provide the sialic acid in spray-dried form as well as in form of sialic acid crystals.

Abstract: Provided are biaryl amides and coumarin-based compounds with modified sugar groups for treatment of diseases associated with heat shock protein pathway. The compounds having the following formulas, wherein variables are as defined herein. Formulae (I), (II), (III), (IV), and (V), Pharmaceutical compositions of the compounds are also provided. These biaryl amides and coumarin-based derivatives with modified sugar groups are useful for treatment and prevention of diseases and disorders, including neurological disorders, such as neurodegenerative diseases and nerve damaging disorders, for example, diabetic peripheral neuropathy.

Abstract: The present invention relates to several novel 1-O-glycosylated sphingoid bases and to a production method thereof, as well as to uses of the 1-O-glycosylated sphingoid bases. Sphingoid bases carrying a vinylogous amide-type protecting group are used herein for the production of 1-O-glycosylated sphingoid bases. These vinylogous amide compounds enable an easy and effective production of 1-O-glycosylated sphingoid bases.

Abstract: Described herein are methods of disrupting (e.g., reducing the viscosity of, or dissolving) a preformed biofilm in a subject, the method comprising: administering to the subject an effective amount of a composition comprising a soluble chitosan or derivatized chitosan wherein the soluble chitosan or derivatized chitosan when administered contacts the preformed biofilm, thereby disrupting (e.g., reducing the viscosity of, or dissolving) the preformed biofilm.

Abstract: Disclosed is a complex of a compound of Formula 1, a stereoisomer thereof, or a tautomer of the compound of Formula 1 or stereoisomer thereof, and a cyclodextrin, in which the complex is an amorphous solid. This disclosure also relates to materials and methods for preparing the complex, to pharmaceutical compositions which contain the complex, and to the use of the complex to treat Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.

Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they relate to the treatment and/or prevention of conditions such as muscle disorders such as polymyositis, dermatomyositis, muscular dystrophy, myasthenia gravis, amyotrophic lateral sclerosis, rhabdomyolysis, and cardiomyopathy, brain disorders including Alzheimer's, stroke, cerebral atrophy, traumatic brain injury, and dementia, aging, diabetes, and cancer, using compounds of Formula (I): as described herein, including pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising these compounds.